Pfizer Reports real-world evidence Data for Pirtobrutinib in Asthma

Pfizer today announced real-world evidence results for pirtobrutinib in patients with asthma. The study demonstrated that pirtobrutinib reduces exacerbation rates compared to standard of care or placebo. These results provide important insights into the treatment of asthma and support the continued development of pirtobrutinib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.